Board of Directors
The Alnylam Board of Directors comprises:
John Clarke, Managing General Partner, Cardinal Partners; founder of Alkermes, Inc. and Cubist Pharmaceuticals, Inc., a founder and chairman of Alnylam Board of Directors
Victor Dzau, M.D., Chancellor for Health Affairs at Duke University, and President and CEO of the Duke University Health System; James B. Duke Professor of Medicine and Director of Molecular and Genomic Vascular Biology at Duke University
John Maraganore, Ph.D., Chief Executive Officer of Alnylam
Vicki L. Sato, Ph.D., Professor of Management Practice, Harvard Business School and Professor of the Practice, Department of Molecular and Cell Biology, Harvard University; Former President and Chief Scientific Officer of Vertex; former Vice President of Research of Biogen, Inc. (now Biogen Idec, Inc)
Paul Schimmel, Ph.D., Ernest and Jean Hahn Professor of Molecular Biology and Chemistry at Scripps Research Institute, National Academy of Sciences, American Academy of Arts and Sciences, and Institute of Medicine member, cofounder of Cubist, Alkermes and Repligen, and a founder and member of the Board of Directors of Alnylam
Edward Scolnick, M.D., Director of the Stanley Center at the Broad Institute of Harvard and MIT; former President of Merck Research Laboratories; National Cancer Institute; National Heart Institute
Phillip Sharp, Ph.D., Institute Professor, The Koch Institute for Integrative Cancer Research, MIT; former Director, McGovern Institute for Brain Research; Nobel Laureate; founder of Biogen, Inc. (now Biogen Idec, Inc.) and Alnylam; National Academy of Sciences
Kevin Starr, Partner, Third Rock Ventures; interim CEO of Agios Pharmaceuticals (a portfolio company of Third Rock).; former Chief Operating Officer and Chief Financial Officer of Millennium Pharmaceuticals, Inc.; former Corporate Controller of Biogen, Inc. (now Biogen Idec, Inc.)
James L. Vincent, Former Chief Executive Officer and Chairman of Biogen, Inc. (now Biogen Idec, Inc.); Board of Trustees for Duke University
